文献速递哮喘

吸入糖皮质激素依从性能否预测哮喘相关结局?队列研究

Does adherence to inhaled corticosteroids predict asthma-related outcomes over time? A cohort study.
PubMed 文献 · Eur Respir J · 2019-12-19

该前瞻性队列纳入法国和英国847例6-40岁持续性哮喘患者,通过电话访谈和短信收集最多2年共3756份报告,采用纵向模型分析ICS依从性与结局的个体间和个体内关系。个体间水平上,平均依从性较高者更可能达到哮喘控制(OR 1.25,95%CI 1.06-1.47),但与急性发作或缓解药物使用无关;个体内水平上,临时提高依从性与同期缓解药物使用增加及后续缓解药物使用减少相关,与哮喘控制或急性发作无关。

要点

  • 长期维持高ICS依从性与更好的哮喘控制相关(OR 1.25,95%CI 1.06-1.47)。
  • 临时提高ICS依从性不改善同期哮喘控制或减少急性发作。
  • 临时提高ICS依从性伴随同期缓解药物使用增加,但后续缓解药物使用减少。

核心结论

  • 长期维持高ICS依从性的患者哮喘控制更好。
  • 临时提高ICS依从性倾向于与同期缓解药物使用增加同时发生,并减少后续缓解药物使用。
  • 结局的个体内变异原因需进一步研究。

研究设计与样本

  • 前瞻性队列研究,纳入法国和英国847例6-40岁持续性哮喘患者,通过计算机辅助电话访谈和短信收集最多2年共3756份报告。
  • 采用纵向模型分析ICS依从性与结局的关系,控制包括严重程度在内的混杂因素。

主要发现

  • 结局存在显著的个体内变异:急性发作91%,哮喘控制59%,缓解药物使用52%。
  • 431份(11.5%)报告提示急性发作,2046份(54.5%)报告提示哮喘控制不佳。
  • 个体间水平:平均依从性较高者更可能报告哮喘控制(OR 1.25,95%CI 1.06-1.47),但与急性发作(OR 0.99,95%CI 0.87-1.12)或缓解药物使用(b -0.0004,95%CI -0.089-0.088)无关。
  • 个体内水平:高于平常的依从性与同期缓解药物使用增加(b 0.092,95%CI 0.053-0.131)和后续缓解药物使用减少(b -0.047,95%CI -0.005- -0.088)相关;与哮喘控制(OR 0.93,95%CI 0.84-1.02)或急性发作(OR 1.04,95%CI 0.94-1.16)无关。

临床怎么用

  • 临床应鼓励哮喘患者长期维持高ICS依从性以改善哮喘控制。
  • 临时增加ICS使用可能不立即改善哮喘控制或减少急性发作,需结合其他管理策略。

局限性

  • 结局的个体内变异原因尚不明确,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Inhaled corticosteroids (ICS) adherence is important for asthma management. Current evidence on the impact of ICS adherence on outcomes is mostly based on correlational analyses of between-person data. Although it is widely acknowledged that asthma outcomes fluctuate over time, evidence on predictors of within-person change is scarce. We aimed to quantify these fluctuations and the longitudinal relationships between ICS adherence and outcomes at both between- and within-person levels.A prospective cohort of persistent asthma patients in France and the UK (n=847, age 6-40 years) provided 3756 reports over up to 2 years via computer-assisted telephone interviews and text messages on ICS adherence, asthma control, reliever medication use and exacerbations. We examined adherence-outcome relationships via longitudinal models, controlling for confounders, including severity.Considerable within-person variability was found for exacerbations (91%), asthma control (59%) and reliever use (52%); 431 (11.5%) reports signalled exacerbations and 2046 (54.5%) poor control. At between-person level, patients with higher average adherence were more likely to report asthma control (OR 1.25, 95% CI 1.06-1.47), but not asthma exacerbations (OR 0.99, 95% CI 0.87-1.12) or lower reliever use (b -0.0004, 95% CI -0.089-0.088). At within-person level, higher-than-usual adherence was associated with higher concomitant reliever use (b 0.092, 95% CI 0.053-0.131) and lower subsequent reliever use (b -0.047, 95% CI -0.005- -0.088); it was unrelated to asthma control (OR 0.93, 95% CI 0.84-1.02) or exacerbations (OR 1.04, 95% CI 0.94-1.16).Patients maintaining high ICS adherence over time have better asthma control. Temporarily increasing ICS adherence tends to be simultaneous to higher reliever use and reduces reliever use later on. Causes of within-person variation in outcomes require more investigation.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Dima AL, van Ganse E, Stadler G, et al. Does adherence to inhaled corticosteroids predict asthma-related outcomes over time? A cohort study. Eur Respir J. 2019. PMID: 31601714. doi:10.1183/13993003.00901-2019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。